MedPath

Efficacy of Silymarin and Vitamin E in the Treatment fatty liver

Phase 3
Conditions
K75.81
on-Alcoholic Fatty Liver Disease.
Nonalcoholic steatohepatitis (NASH)
Registration Number
IRCT20081110001444N6
Lead Sponsor
Shahid Sadoughi University of Medical Sciences-Yazd, Iran
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
80
Inclusion Criteria

The inclusion criteria were : NAFLD confirmed through abdominal ultrasonography, persistent elevation in the level of alanine aminotransferase (ALT) within the last six months for one and a half times more than the upper normal limit, fatty changes diagnosed through ultrasonography, and over 20 years of age.

Exclusion Criteria

The exclusion criteria were autoimmune hepatitis, alpha-1 antitrypsin deficiency, chronic hepatitis B or C, hemochromatosis, and Wilson’s disease. Patients with a history of diabetes, daily consumption ethanol, severe cardiac, pulmonary, renal, or psychological problems, positive pregnancy test, and the use of drugs such as statins, fibrates, anti-convulsants, NSAID, acetaminophen, warfarin, metronidazole, anti-depressants, or anti-psychotics were also excluded from the study.

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
ALanin aminotransferas measurements. Timepoint: They were received at the baseline and then after four months for ALT measurements. Method of measurement: autoanlizer.;Ultrasonographic evaluations of their liver. Timepoint: first and four months later. Method of measurement: General Electric ultrasound device,.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath